Haiying Xu

23.8k citations

49 papers · 8.1k indexed · 3 hit papers · h-index 32

Oncology top 0.2%
Immunology top 0.5%
Pulmonary and Respiratory Medicine top 1%
Molecular Biology top 10%
Cancer Research top 2%

Co-authors: Janis M. Taube Lieping Chen Robert A. Anders Drew M. Pardoll Suzanne L. Topalian Julie R. Brahmer Jung Ho Kim Alison Klein
Topics: Immunotherapy and Immune Responses (22 papers)Cancer Immunotherapy and Biomarkers (22 papers)CAR-T cell therapy research (11 papers)
Cited by: Oncology Immunology Cancer Research
Journals: Proceedings of the National Academy of Sciences Nature Communications Journal of Clinical Oncology
Partner nations: United States China Australia

In The Last Decade

Haiying Xu

49 papers receiving 8.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

2014 1.9k citations Janis M. Taube, Alison Klein et al. Clinical Cancer Research profile →
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

2012 1.7k citations Janis M. Taube, Robert A. Anders et al. profile →
Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

2015 643 citations Kristin J. Lastwika, Willie Wilson et al. Cancer Research profile →

Peers

Countries citing papers authored by Haiying Xu

Since Specialization

Citations

This map shows the geographic impact of Haiying Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haiying Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haiying Xu more than expected).

Fields of papers citing papers by Haiying Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haiying Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haiying Xu. The network helps show where Haiying Xu may publish in the future.

Co-authorship network of co-authors of Haiying Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Haiying Xu. A scholar is included among the top collaborators of Haiying Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haiying Xu. Haiying Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Whole-Slide Imaging, Mutual Information Registration for Multiplex Immunohistochemistry and Immunofluorescence 2023 ·Laboratory Investigation ·(unknown),Benjamin Green,Margaret Eminizer,(unknown),Steve Lu,Elizabeth L. Engle,Haiying Xu,Aleksandra Ogurtsova,Jonathan R. Lai,(unknown),J. Roskes,Julie S. Deutsch,Janis M. Taube,Joel Sunshine,Alexander S. Szalay	4
2	CD30 Lateral Flow and Enzyme-Linked Immunosorbent Assays for Detection of BIA-ALCL: A Pilot Study 2023 ·Cancers ·(unknown),Haiying Xu,(unknown),Jason T. Machan,Mark W. Clemens,Honghua Hu,Anand K. Deva,Caroline Glicksman,Patricia McGuire,William P. Adams,David A. Sieber,Mithun Sinha,Marshall E. Kadin	1
3	Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery 2021 ·Cancer Immunology Research ·Nicolás A. Giraldo,Sneha Berry,Étienne Becht,Deniz Ateş Özdemir,Kara M. Schenk,Elizabeth L. Engle,Benjamin Green,Peter Nguyen,Abha Soni,Julie E. Stein,Farah Succaria,Aleksandra Ogurtsova,Haiying Xu,Raphaël Gottardo,Robert A. Anders,Evan J. Lipson,Ludmila Danilova,Alexander S. Baras,Janis M. Taube	6
4	PD-L1 expression in inflammatory myofibroblastic tumors 2018 ·Modern Pathology ·Tricia R. Cottrell,(unknown),Christopher D. Gocke,Haiying Xu,Aleksandra Ogurtsova,Janis M. Taube,Deborah Belchis	16
5	PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison 2017 ·Clinical Cancer Research ·Joel Sunshine,Peter Nguyen,Genevieve J. Kaunitz,Tricia R. Cottrell,Sneha Berry,Jessica Esandrio,Haiying Xu,Aleksandra Ogurtsova,Karen B. Bleich,Toby C. Cornish,Evan J. Lipson,Robert A. Anders,Janis M. Taube	109
6	Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade 2017 ·Journal for ImmunoTherapy of Cancer ·Evan J. Lipson,Mohammed Lilo,Aleksandra Ogurtsova,Jessica Esandrio,Haiying Xu,(unknown),Megan D. Schollenberger,William H. Sharfman,Janis M. Taube	115
7	PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast 2017 ·Modern Pathology ·Elizabeth D. Thompson,Janis M. Taube,(unknown),Aleksandra Ogurtsova,Haiying Xu,Rajni Sharma,Alan K. Meeker,Pedram Argani,Leisha A. Emens,Ashley Cimino‐Mathews	36
8	Melanoma subtypes demonstrate distinct PD-L1 expression profiles 2017 ·Laboratory Investigation ·Genevieve J. Kaunitz,Tricia R. Cottrell,Mohammed Lilo,Valliammai Muthappan,Jessica Esandrio,Sneha Berry,Haiying Xu,Aleksandra Ogurtsova,Robert A. Anders,Alexander H. Fischer,Stefan Kraft,Meg R. Gerstenblith,Cheryl L. Thompson,Kord Honda,Jonathan D. Cuda,Charles G. Eberhart,James T. Handa,Evan J. Lipson,Janis M. Taube	157
9	The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma 2016 ·Cancer Immunology Research ·Maria Libera Ascierto,Tracee L. McMiller,Alan E. Berger,Ludmila Danilova,Robert A. Anders,George J. Netto,Haiying Xu,Theresa S. Pritchard,Jinshui Fan,Chris Cheadle,Leslie Cope,Charles G. Drake,Drew M. Pardoll,Janis M. Taube,Suzanne L. Topalian	133
10	Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma 2016 ·Aesthetic Surgery Journal ·Marshall E. Kadin,Anand K. Deva,Haiying Xu,John Morgan,Pranay D. Khare,Roderick A.F. MacLeod,Bruce W. Van Natta,William P. Adams,Garry S. Brody,Alan L. Epstein	115
11	Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancerbreakdown → 2015 ·Cancer Research ·Kristin J. Lastwika,Willie Wilson,Qing Kay Li,Jeffrey W. Norris,Haiying Xu,Sharon R. Ghazarian,Hiroshi Kitagawa,Shigeru Kawabata,Janis M. Taube,Sheng Yao,Linda N. Liu,Joell J. Gills,Phillip A. Dennis	643
12	Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade 2015 ·Clinical Cancer Research ·Janis M. Taube,Geoffrey D. Young,Tracee L. McMiller,Shuming Chen,January T. Salas,Theresa S. Pritchard,Haiying Xu,Alan K. Meeker,Jinshui Fan,Chris Cheadle,Alan E. Berger,Drew M. Pardoll,Suzanne L. Topalian	196
13	B7-H3 Promotes Pathogenesis of Autoimmune Disease and Inflammation by Regulating the Activity of Different T Cell Subsets 2015 ·PLoS ONE ·Liqun Luo,Gefeng Zhu,Haiying Xu,Sheng Yao,Gang Zhou,Yuwen Zhu,Koji Tamada,Lanqing Huang,Andrew S. Flies,Megan Broadwater,William Ruff,Jan M. A. van Deursen,Ignacio Melero,Zhou Zhu,Lieping Chen	96
14	PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation 2014 ·Cancer Immunology Research ·Nemanja Rodić,Robert A. Anders,James R. Eshleman,Ming-Tseh Lin,Haiying Xu,Jung Ho Kim,Katie Beierl,Shuming Chen,Brandon Luber,Hao Wang,Suzanne L. Topalian,Drew M. Pardoll,Janis M. Taube	42
15	Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapybreakdown → 2014 ·Clinical Cancer Research ·Janis M. Taube,Alison Klein,Julie R. Brahmer,Haiying Xu,Xiaoyu Pan,Jung Ho Kim,Lieping Chen,Drew M. Pardoll,Suzanne L. Topalian,Robert A. Anders	1873
16	PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment 2014 ·Journal of Neuro-Oncology ·Dimitrios Mathios,Jacob Ruzevick,Christopher M. Jackson,Haiying Xu,Sagar Shah,Janis M. Taube,Peter C. Burger,Edward F. McCarthy,Alfredo Quiñones‐Hinojosa,Drew M. Pardoll,Michael Lim	60
17	B7-H2 Is a Costimulatory Ligand for CD28 in Human 2011 ·Immunity ·Sheng Yao,Yuwen Zhu,Gefeng Zhu,Mathew M. Augustine,Linghua Zheng,Diana Goode,Megan Broadwater,William Ruff,Sarah J. Flies,Haiying Xu,Dallas B. Flies,Liqun Luo,Shengdian Wang,Lieping Chen	118
18	Potential Role of Decoy B7-H4 in the Pathogenesis of Rheumatoid Arthritis: A Mouse Model Informed by Clinical Data 2009 ·PLoS Medicine ·Takeshi Azuma,Gefeng Zhu,Haiying Xu,A. Rietz,Charles G. Drake,Eric L. Matteson,Lieping Chen	59
19	Leucocyte‐associated immunoglobulin‐like receptor‐1 is an inhibitory regulator of contact hypersensitivity 2009 ·Immunology ·Ryusuke Omiya,Fumihiko Tsushima,Hidehiko Narazaki,Yukimi Sakoda,Atsuo Kuramasu,Hyun Soo Kim,Haiying Xu,Hideto Tamura,Gefeng Zhu,Lieping Chen,Koji Tamada	16
20	B7-H4–deficient mice display augmented neutrophil-mediated innate immunity 2008 ·Blood ·Gefeng Zhu,Mathew M. Augustine,Takeshi Azuma,Liqun Luo,Sheng Yao,Sudarshan Anand,A. Rietz,Jiaqiang Huang,Haiying Xu,Andrew S. Flies,Sarah J. Flies,Koji Tamada,Marco Colonna,Jan M. A. van Deursen,Lieping Chen	68

About Haiying Xu

Haiying Xu is a scholar working on Immunology, Oncology and Dermatology, having authored 49 papers that have together received 8.1k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (22 papers), Cancer Immunotherapy and Biomarkers (22 papers) and CAR-T cell therapy research (11 papers). The work is most often cited by research in Oncology (6.3k citations), Immunology (4.0k citations) and Cancer Research (786 citations). Haiying Xu has collaborated with scholars based in United States, China and Australia. Frequent co-authors include Janis M. Taube, Lieping Chen, Robert A. Anders, Drew M. Pardoll, Suzanne L. Topalian, Julie R. Brahmer, Jung Ho Kim, Alison Klein, Xiaoyu Pan and Rajni Sharma. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact